Rapid mast cell generation from Gata2 reporter pluripotent stem cells

Citation for published version:

Digital Object Identifier (DOI):
10.1016/j.stemcr.2018.08.007

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published In:
Stem Cell Reports

Publisher Rights Statement:
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Rapid Mast Cell Generation from Gata2 Reporter Pluripotent Stem Cells

Mari-Lis Kauts,1,2 Bianca De Leo,2 Carmen Rodríguez-Seoane,2 Roger Ronn,2 Fokion Glykofrydis,2 Antonio Maglittio,2 Polynikis Kaimakis,1 Margarita Basí,1 Helen Taylor,3 Lesley Forrester,3 Adam C. Wilkinson,4 Berthold Göttgens,4 Philippa Saunders,2 and Elaine Dzierzak1,2,*

1Erasmus Stem Cell Institute, Department of Cell Biology, Erasmus Medical Center, Rotterdam, Netherlands
2MRC Centre for Inflammation Research, Queen’s Medical Research Institute, University of Edinburgh, 47 Little France Crescent, Edinburgh EH16 4TJ, UK
3MRC Centre for Regenerative Medicine Inflammation Research, University of Edinburgh, Edinburgh, UK
4Wellcome Trust and MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, UK
*Correspondence: elaine.dzierzak@ed.ac.uk
https://doi.org/10.1016/j.stemcr.2018.08.007

SUMMARY

Mast cells are tissue-resident immune cells. Their overgrowth/overactivation results in a range of common distressing, sometimes life-threatening disorders, including asthma, psoriasis, anaphylaxis, and mastocytosis. Currently, drug discovery is hampered by use of cancer-derived mast cell lines or primary cells. Cell lines provide low numbers of mature mast cells and are not representative of in vivo mast cells. Mast cell generation from blood/bone marrow gives poor reproducibility, requiring 8–12 weeks of culture. Here we report a method for the rapid/robust production of mast cells from pluripotent stem cells (PSCs). An advantageous Gata2Venus reporter enriches mast cells and progenitors as they differentiate from PSCs. Highly proliferative mouse mast cells and progenitors emerge after 2 weeks. This method is applicable for rapid human mast cell generation, and could enable the production of sufficient numbers of physiologically relevant human mast cells from patient induced PSCs for the study of mast cell-associated disorders and drug discovery.

INTRODUCTION

As tissue-resident immune cells, mast cells are the key effectors in common immunological disorders affecting worldwide populations. These include allergies, asthma, eosinophilic esophagitis, celiac disease, mastocytosis, atopic dermatitis, and psoriasis. A characteristic feature of mast cells is the large cytoplasmic granules containing proteases that are released upon activation, for example during an allergic reaction. Activation of mast cells occurs via a number of different agents: immunoglobulin E (IgE), damage-/pathogen-induced molecules, and complement components (reviewed in Rudich et al., 2012). These cells act viscerally in the CNS and also at the blood-brain barrier, causing a wide variety of symptoms in complex diseases that are difficult and often impossible to diagnose. More recently they are suspected to affect pain and neuroinflammation in endometriosis (Theoharides et al., 2015). Strategies to limit the damaging effects of mast cells are needed.

Dependent upon their tissue of residence, mast cells differentially produce a variety of proteases, such as chymase, tryptase and/or histamine (Schwartz and Austen, 1980). Murine connective tissue-type mast cells express heparin, high concentrations of histamine, tryptases (mMCP-6 and -7), chymases (mMCP-4 and -5), and carboxypeptidase A (CPA), whereas mucosal mast cells lack heparin and express low levels of histamine and chymases (mMCP-1 and -2) (Galli et al., 2011). Mast cells in the human also differentially express chymase and tryptase, with classical mast cells being tryptase+chymase+ and tryptase-chymase+ (Bischoff, 2007; Weller et al., 2007). Recently a new mast cell type (tryptase+chymase+) has been found in endometrial tissue (De Leo et al., 2017). The fact that these endometrial mast cells express steroid receptors suggests that mast cell function is altered by the local microenvironment.

Treatment options focusing on the modulation of mast cell activity are limited, and the development of new therapies is hampered by challenges in generating sufficient phenotypically mature mast cells for biomedical discovery and drug screening (Holm et al., 2006; Saito et al., 2006; Shimizu et al., 2002; Wang et al., 2006). Direct isolation of mast cells is inefficient (Dahlin et al., 2016) and results in an altered phenotype. Moreover, the ex vivo generation of mast cells from human blood precursors involves extended culture periods, expensive reagents, and low/variable yields (Kirshenbaum and Metcalfe, 2006). Pluripotent stem cells (PSCs) offer an alternative source for obtaining mature mast cells for research. However, the published protocols are time consuming, as mast cells emerge after 4–8 weeks of mouse PSC culture (Moller et al., 2007; Tsai et al., 2002; Westerberg et al., 2012; Yamaguchi et al., 2013) and only after 5–10 weeks of human PSC culture (Kovarova et al., 2010) (Table 1). Further prolonged culture is needed to increase mast cell yield, as the cells are cumulatively harvested and do not enable prompt production of large numbers of mast cells. The lack of an efficient protocol to rapidly obtain large numbers of mature mast cells for research has restricted drug development and progress in understanding and treating mast cell-related disorders; thus, new approaches for mast cell production are needed.
TABLE 1. Duration of Cultures Used for Mast Cell Generation from Different Cell/Tissue Sources

<table>
<thead>
<tr>
<th>Source</th>
<th>Culture Time</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>hPB</td>
<td>8–12 weeks</td>
<td>Kirshenbaum and Metcalfe, 2006; Saito et al., 2006; Wang et al., 2006</td>
</tr>
<tr>
<td>hCB</td>
<td>12 weeks</td>
<td>Holm et al., 2006</td>
</tr>
<tr>
<td>hBM</td>
<td>12 weeks</td>
<td>Shimizu et al., 2002</td>
</tr>
<tr>
<td>mESC</td>
<td>4–8 weeks</td>
<td>Moller et al., 2007; Tsai et al., 2002; Westerberg et al., 2012</td>
</tr>
<tr>
<td>hiPSC</td>
<td>5 weeks</td>
<td>Igarashi et al., 2018</td>
</tr>
<tr>
<td>G2V mESC</td>
<td>14–21 days</td>
<td>this study</td>
</tr>
<tr>
<td>G2V hESC/iPSC</td>
<td>12–16 days</td>
<td>this study</td>
</tr>
</tbody>
</table>

Duration (weeks/days) of cultures for human (h) mast cell generation from progenitors isolated from primary tissue sources such as peripheral blood (hPB), cord blood (hCB), and bone marrow (hBM); from wild-type and progenitors isolated from primary tissue sources such as peripheral blood (G2V hESC/iPSC 12–16 days this study), human embryonic stem cells (mESC); and human ESCs (hESC) and induced pluripotent stem cells (iPSC). References for each of the studies are indicated.

RESULTS

Abundant Production of Phenotypic Mast Cells from Mouse ESCs

Our recent data show that all functional HPCs generated in mouse ESC (mESC) differentiation cultures are Gata2 expressing, with a peak of HPC activity at day 10 of ESC culture (Kauts et al., 2016, 2018). With an initial aim to test whether further hematopoietic induction would lead to the development of transplantable HSC/HPC, a three-stage culture was established. In stage 1, G2V mESCs were differentiated to embryoid bodies (EBs) for 10 days (Figure 1A). Venus+ (V+) cells (1.6% of viable EB-derived cells; Figure 1B) were harvested and in stage 2, cultured on a monolayer of OP9 stromal cells for 4 days. The average number of V+ cells obtained from day-10 EBs (3 × 10^4 starting ESCs) was 1.5 ± 0.3 × 10^4 (Table 2). Round non-adherent hematopoietic cells appeared in the OP9 co-culture after 2–3 days (Figure 1C) and after 4 days, 37% ± 6.8% of the cells expressed high levels of Venus (Figure 1D). Only V+ cells specifically co-expressed the pan-leukocyte marker CD45, and 99% ± 0.6% of V+CD45+ cells were positive for the CKIT (CD117) HSC/HPC marker (Figure 1E). In the stage 3 culture, day-14 V+ cells were seeded in methylcellulose and progenitor numbers analyzed at days 18–21.

To assess the V+CD45+ cell population after stage 2, we analyzed mature blood lineage (Lin) marker expression: Mac1 (macrophage), GR1 (granulocyte/monocyte), CD19 (lymphocyte), and TER119 (erythroid) (Figure 1F). None of these markers were expressed on day-14 V+CD45+ cells. As phenotypic HSCs/HPCs are Lin− and express GATA2 (Kaimakis et al., 2016; Kauts et al., 2016, 2018), CKIT (Sanchez et al., 1996) and CD45 (McKinney-Freeman et al., 2009; North et al., 2002), we examined whether functional HSC/HPC-like cells were generated in the differentiation culture by the in vivo colony forming unit-spleen assay (CFU-S). At day 8 post transplantation of day-14 V+CD45+Lin− cells into lethally irradiated adult mice (two injected with 1,200 and one injected with 20,000 cells), no donor-derived CFU-S activity was found (Figure 1G).

Since mast cells are also known to express GATA2, CKIT, and CD45 (Dahlin et al., 2016; Jippo et al., 1996; Sasaki et al., 2016), we examined differentiated ESCs for expression of the high-affinity IgE receptor 1α (FcεRIα), a mast cell marker. At day 10, 35%–36% of V+ cells were CKIT+ (Figure 1H, upper panels); 37% of these V+CKIT+ cells were CD45+ and only 2.5% of V+CKIT+ cells were FcεRIα−. In contrast, 83% ± 4.4% of V+CD45+CKIT+ cells after day 14 were FcεRIα+ (Figure 1H, lower right panel). 5.7% ± 3.5% of day-14 V+CD45+ cells showed some low-level CKIT expression, but none of these cells were FcεRIα− (Figure 1H, lower left panel). These data suggest that at day 14,
most V^-CKIT^-CD45^- cells are mast cells/progenitors and that at day 10 most V^-CKIT^-CD45^-/^- cells are phenotypic HPCs. As it is thought that mast and basophilic cells express higher levels of GATA2 than HPCs (Kaimakis et al., 2016), the mean fluorescent intensity (MFI) of VENUS expression was examined (Figure 1I). Compared with day-10 differentiated cells, the day-14 cells exhibited a 3.5-fold higher MFI. To further verify the mast cell phenotype of the ESC-derived V^- cells, we examined the expression of a basophilic marker, CD49B, on these cells by fluorescence-activated cell sorting (FACS) analysis (Figure S1). Basophils are known to be CKIT^+^, FcεRIα^+^, and CD49B^+^. Compared with cultured mouse bone marrow CD45^-^ cells (Figure S1C), which show both CD49B^+^ mast cells and CD49B^-^ basophils, only a negligible percentage of ESC-derived cells (Figure S1A) and cultured peritoneal mast cells (Figure S1B) were CD49B^+^, thus demonstrating that the great majority of ESC-derived cells have acquired a mast cell and/or mast cell progenitor phenotype after 14 days.

**Development and Expansion of G2V Mast Cells**

To analyze the growth capacity of the V^- mast cells/progenitors, we plated single V^- cells harvested from day-4 OP9 co-cultures in methylcellulose stage 3 culture. After 3–4 days, macroscopic homogeneous colonies appeared (Figure 2A), indicating a large degree of rapid expansion. In total, a starting culture of 3 × 10^5 ESCs can yield up to 3.8 × 10^6 mature mast cells (average 1.6 ± 0.5 × 10^6) (Table 2). This is up to 8-fold more cells generated in 21 days than previously reported after 5 or more weeks of mESC culture (0.5 × 10^6 cells) (Westerberg et al., 2012), and 2-fold more mast cells 1 week earlier than from mouse iPSCs (Yamaguchi et al., 2013).

Mast cell identity was confirmed by toluidine blue staining (cytoplasmic granule-specific). One hundred percent of the cells after stage 3 culture were toluidine blue positive, indicating a large degree of rapid expansion. In total, a starting culture of 3 × 10^5 ESCs can yield up to 3.8 × 10^6 mature mast cells (average 1.6 ± 0.5 × 10^6) (Table 2). This is up to 8-fold more cells generated in 21 days than previously reported after 5 or more weeks of mESC culture (0.5 × 10^6 cells) (Westerberg et al., 2012), and 2-fold more mast cells 1 week earlier than from mouse iPSCs (Yamaguchi et al., 2013).

G2V Mast Cells Are Activated upon Extracellular Stimulation

Allergic responses in vivo result from the activation and degranulation of mast cells. To test whether G2V mast cells are functionally responsive, we treated cells with compound 48/80 (c48/80) (Lagunoff and Rickard, 1983), a known secretagog of mast cells. After 60 min of c48/80 (400 μg/mL) a significantly 1.6-fold higher tryptase level was found in the cell media as compared with the control unstimulated sample (Figure 2F). An FcεRIα-mediated degranulation assay was also performed on G2V-mESC-derived mast cells and control mouse peritoneal mast cells (Figure 2G). In the absence of activation, some leakiness (as measured by percentage of β-hexosaminidase release) was observed. However, when IgE-sensitized G2V-mESC-derived mast cells were stimulated by adding antigen to the ESC-derived mast cells, a significant 2-fold increase in degranulation occurred that was in accordance with the increased degranulation levels (also significant) seen in the peritoneal mast cell controls. Together, these data
Figure 1. G2V mESC Differentiation and VENUS Enrichment Facilitates Rapid and Robust Mast Cell Generation

(A) Three-stage differentiation protocol for mast cell production. Stage 1 is hematopoietic commitment in 10-day embryoid body (EB) culture. At day 10, GATA2VENUS⁺ (V⁺) cells are sorted and plated onto OP9 cells in stage 2, where mast cell commitment is induced to yield MAST CELLS.
demonstrate that the G2V ESC-derived mast cells can be activated and respond to common mast cell activating extracellular stimuli, triggering the release of chemical mediators.

**Human G2V Reporter PSC Differentiation as an Innovative Approach for Rapid Human Mast Cell Production**

In studies related to the involvement of mast cell in endometriosis, we generated mast cells from human CD34+ peripheral blood cells by a widely used method (Kirshenbaum and Metcalfe, 2006). Density gradient-enriched CD34+ progenitor cells were cultured in serum-free medium with growth factors for 8 weeks (Figure S2A). At 2 and 3 weeks, only a few low toluidine blue-stained cells were detected, whereas intensely blue cells indicative of mast cells predominated in 8-week cultures. Further characterization showed upregulated expression of human mast cell protease/receptor genes (Figure S2B). Little to no expression was found at week 1, but statistically significant 20-fold to 70-fold increases of TPSAB1 (tryptase α/β isoforms) and CMA1 (chymase1) expression were found at 4 and 8 weeks. PAR2 (protease activated receptor2) and HR1 (histamine receptor1) expression showed significant increases only at week 8. These results are consistent with the presence of mast cells at week 8 of PBC CD34+ culture. Also, a human mast cell line, HMC-1, showed significantly lower expression of the mast cell genes TPSAB1, CMA1, PAR2, and HR1 compared with 8-week differentiated CD34+ PBCs (Figure S2C), thus demonstrating that HMC1 is not a relevant alternative to overcome the challenge of long duration of mature human mast cell production, and highlighting the need for developing novel culture methods.

Our ability to rapidly produce mast cells from the G2V reporter mESCs, together with the known conservation in hematopoietic development and Gata2 expression/function in mouse and man, suggested that the GATA2 reporter could be applied to human PSCs (hPSCs) for the production of human mast cells. Thus, we established GATA2Venus reporter human ESCs (hESCs) and iPSCs in a strategy similar to that used with G2V mESCs. A 2A-Venus sequence was introduced into the human GATA2 (hGATA2) 3` UTR by the CRISPR/Cas9 method (Figure S3A). One clone of GATA2Venus reporter human ESCs (G2V-hESC) and two independent clones of iPSCs (G2V-hiPSC1; G2V-hiPSC2) were characterized (Figure S3B) for GATA2 expression and hematopoietic differentiation. V+ sorted cells from day-6 differentiation cultures of all three cell lines expressed high levels of GATA2 compared with V− cells (Figure S3C). At day 12, flow cytometry showed that 38%–70% of cells were V+ and that 6%–18% of V+ cells expressed the CD41 hematopoietic marker (Figure S3D). Moreover, most HPCs (>90%) were enriched in the V+ fraction of differentiated G2V hESCs and hiPSCs (Figure S2E) as shown by in vitro CFU-cell assays. All erythroid and myeloid hematopoietic colony types were present. These results are in line with previous analyses of mESCs (Kauts et al., 2016, 2018) and hESCs/iPSCs (Huang et al., 2015), and show that GATA2 is an efficient reporter for human HPCs.

To test whether our rapid Gata2 reporter-based mouse mast cell generation method is also applicable for mast cell generation from hPSCs, we applied the staged differentiation culture protocol to the three independent cell lines, G2V-hiPSC-1, G2V-hiPSC-2, and G2V-hESC. Following 7, 8, and 11 days of differentiation, respectively, cells were sorted based on Venus expression and co-cultured with OP9 cells for 4–5 days. Of the $3.4 \times 10^4$, $8.9 \times 10^4$, and
DISCUSSION

The Gata2 reporter PSC approach represents a significant advance in the rapid production of mast cells for research (Table 1). Compared with previously published protocols using limited sources of cells such as human blood (peripheral blood, umbilical cord) and bone marrow, and unlimited PSC sources, the staged G2V differentiation and enrichment method shortens culture duration considerably (by 1 week for mouse and several weeks for human cultures). This time-saving and resource-efficient method raises prospects for production of mast cells (including patient-specific) for high-throughput drug discovery and mechanistic studies on mast cell-related disorders.

Gata2 Expression as a Reporter for Mast Cells

The Gata2 transcription factor is known to be expressed in HSCs, HPCs, and mast cells (Jippo et al., 1996; Kaimakis et al., 2016). As a nuclear factor it is not amenable to antibody-mediated viable cell enrichment by FACS sorting, and the generation of reporters that accurately mimic Gata2 without disrupting its expression levels or protein function has been difficult (Minegishi et al., 2003). We achieved faithful reporter gene expression by inserting an IRESVenus sequence into the Gata2 3’ UTR, thus precluding disruption of the coding sequences or regulatory elements, or functional modification (as in a fusion protein) of Gata2. Such an approach allows for the parallel expression of the Venus reporter together with the proper qualitative and quantitative expression of Gata2 (Eich et al., 2018). Importantly, our Gata2 reporter approach has been verified in vivo (Kaimakis et al., 2016) and shown to provide the appropriate physiologic levels of Gata2 expression for undisturbed hematopoietic development and differentiation. Venus protein levels correctly correspond to Gata2 protein levels (Eich et al., 2018), thus guaranteeing appropriate reporting of GATA2 expression in the in vitro G2V ESC/iPSC models.

FACS analysis revealed varying levels of Venus expression in cells from G2V mESC differentiation cultures. We have shown that a significant 3.5-fold increase in Venus MFI between day 10 and day 14 of differentiation (Figure 1I) corresponds to the appearance of mast cells, thus supporting the view that the direct induction of high GATA2 expression is a prerequisite for the rapid commitment to the mast cell lineage (Sasaki et al., 2016) and for the activation of mature mast cells (Masuda et al., 2007).

G2V Mast Cell Expansion Features

In addition to producing mast cells, we found that the staged G2V mESC culture system produces self-renewing mast cell progenitors. Replating experiments revealed large increases in mast cell output over time. While it is known that interleukin-3 (IL-3) and stem cell factor (SCF) lead to increased mast cell output and function (Ito et al., 2012; Lantz et al., 1998; Yamaguchi et al., 2013), our G2V mESC produce these cells in 2–3 weeks, rather than the 4–12 weeks in other culture systems. Most similar to our

Table 2. Mast Cell Generation and Frequency in the G2V mESC Multistep Cultures

<table>
<thead>
<tr>
<th>Experiment</th>
<th>Stage 1: V+ Cells from 3 x 10⁴ ESCs</th>
<th>Stage 2: MC/MCp from 3 x 10⁴ ESCs</th>
<th>Stage 3: MC Yield from 3 x 10⁵ ESCs</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>11,504</td>
<td>14,923</td>
<td>1,242,200</td>
</tr>
<tr>
<td>2</td>
<td>30,000</td>
<td>2,781</td>
<td>937,000</td>
</tr>
<tr>
<td>3</td>
<td>7,541</td>
<td>2,623</td>
<td>3,834,375</td>
</tr>
<tr>
<td>4</td>
<td>9,653</td>
<td>1,990</td>
<td>570,313</td>
</tr>
<tr>
<td>5</td>
<td>20,087</td>
<td>6,421</td>
<td>1,156,250</td>
</tr>
<tr>
<td>6</td>
<td>13,764</td>
<td>1,986</td>
<td>1,906,250</td>
</tr>
<tr>
<td>Mean</td>
<td>15,425</td>
<td>5,936</td>
<td>1,607,731</td>
</tr>
<tr>
<td>±SEM</td>
<td>±3,405</td>
<td>±1,986</td>
<td>±479,952</td>
</tr>
</tbody>
</table>

3.4 × 10⁴ viable cells harvested from the G2V-hiPSC-1, G2V-hiPSC-2, and G2V-hESC OP9 co-cultures, 4.3%, 5.2%, and 3.0%, respectively were Venus expressing, yielding 278, 241, and 906 CKIT+FCR+Rlx+ phenotypic mast cells (7.8%, 5.5%, and 19%, respectively) (Figure 3A). No CKIT+FCR+Rlx+ cells were detected in the V− fractions. In further experiments we focused on the G2V hiPSC-1 line (Figure 3B). After 10 days of differentiation and 4 days of OP9 co-culture, 16.30% ± 4.82% CKIT+FCR+Rlx+ cells were detected in the cultures of V+ cells, whereas no to few CKIT+FCR+Rlx+ cells (0.42% ± 0.33%) were found in the V− cell cultures (n = 3; p = 0.030). Toliudine blue and rapid Romanowsky staining of cells from G2V-hiPSC1 expanded cultures confirmed mast cell morphology (Figure 3C). Moreover, qRT-PCR verified increased expression of the mature mast cell protease, TPSAB1 in differentiated G2V-hiPSC1 as compared with undifferentiated cells (Figure 3D). The consistency of the results from the G2V-hESC and G2V-hiPSC clones indicate that our staged culture and enrichment approach, although not as quantitatively efficient as the G2V-mESC cultures, delivers a promising platform for the generation of human mast cells within 12–16 days of culture initiation.

REFERENCES


Yamaguchi et al. used co-cultures with OP9 cells to achieve the production of $6.5 \times 10^6$ mast cells from $1 \times 10^5$ mouse iPSCs in 4 weeks (Yamaguchi et al., 2013). From a starting population of $3 \times 10^4$ G2V mESCs, we have achieved up to $3.8 \times 10^6$ mast cells within 3 weeks (or $12.65 \times 10^6$ mast cells from $1 \times 10^5$ G2V mESC), thus demonstrating not only a more rapid production but a more abundant production of mast cells. Following stage 2, on average every 1:2 to 1:6 Gata2+ cell was an MCp and gave rise to a homogeneous colony containing more than 500 mature mast cells. While the Gata2 reporter-mediated enrichment focuses the co-culture system on hematopoietic progenitors and MCp, we are currently attempting to further shorten the culture period and mast cell output of mESC by other modifications to the culture conditions.

**GATA2 Reporter Can Be Exploited for Rapid Human Mast Cell Generation**

Our staged ESC culture takes advantage the Gata2 reporter together with OP9 stromal cell co-culture for high-efficiency mouse mast cell induction. Approximately 1%–2% of cells after stage 1 culture are GATA2 expressing and the OP9 co-culture step results in close to 100% differentiation of GATA2-expressing mESC-derived cells to mast cells/mast cell progenitors. We found this method to be applicable to G2V human ESCs/iPSCs. Three independent lines of G2V PSCs were cultured according to the multistep protocol.
except under serum-free conditions and with different cytokines in step 1. In contrast to mouse cultures, high percentages (40%-70%) of GATA2-expressing cells were observed after stage 1 (25- to 44-fold more). Following stage 2 co-culture on OP9 cells, almost all mast cell/mast cell progenitors were found in the GATA2+ fraction, as was found for the mouse stage 2 cultures. However, the frequency of human CKIT+FCεRIα+ cells was many times lower. Nonetheless, human mast cells can be obtained within 12–16 days of differentiation and Gata2 reporter would enable the production of human mast cells that could be enriched to high homogeneity, in contrast to mast cells derived from wild-type non-reporter PSCs.

Our study highlights possible species-specific differences between mPSCs and hPSCs and/or culture requirements for quantitatively efficient mast cell production. For example, mESCs are thought to be naive whereas hESCs/hiPSCs are primed and somewhat differentiated (Weinberger et al., 2016). It will be interesting to test whether the efficiency of hESC/hiPSC hematopoietic differentiation increases in serum-containing cultures. Moreover, OP9 cells are neonatal mouse bone marrow stromal cells that efficiently support mouse hematopoietic cell development and differentiation (Lynch et al., 2011). It would be beneficial to find an equivalent human cell line for the co-culture step in the hESC/hiPSC method. And, by extension, examination of which specific molecules produced by OP9 cells are relevant to mast cell differentiation of mESCs would allow for identification and testing of the relevant human homologs. These and other approaches for increasing the

Figure 3. Generation of Human GATA2VENUS Mast Cells
(A) The differentiation approach (Figure 1A) was applied to G2V-hESC/hiPSC to generate human mast cells. V+ cells were sorted from three independent cell lines (day-7 G2V-hiPSC1, day-8 G2V-hiPSC2, and day-11 G2V-hESC differentiated EBs) and subjected to OP9 co-culture. After 4 days (G2V-hiPSC1) or 5 days (G2V-hiPSC2, G2V-hESC) in step 2 culture, V+ and V− cells were analyzed for mast cell markers CKIT and FCεRIα by FACS. Percentages of cells in gated regions are shown (n = 1 independent experiment for each cell line/time frame).
(B) Bar graph showing percentages (mean ± SEM) of CKIT+FCεRIα+ cells obtained from the VENUS+ and VENUS− fractions of cells harvested from day-10 differentiated and 4-day co-cultured G2V-hiPSC1 cells (n = 3; p = 0.030).
(C) Image of toluidine blue (left) and rapid Romanowsky (right) stained mast cells generated after 5 days of step 3 expansion culture. Scale bars, 50 µm (left) and 10 µm (right).
(D) Gene expression analysis of mast cell-specific protease tryptase (TPSAB1) in undifferentiated (n = 2) and differentiated G2V-hiPSC1 (n = 3) cells. GAPDH controlled for mRNA quantity. Relative expression levels were normalized to OP9 TPSAB1 expression, which was set as 1.
efficiency of human mast cell production are under investigation and will open up opportunities for the controlled production of mast cells from patients suffering from highly heterogeneous mast cell disorders such as mastocytosis (Jawhar et al., 2017). CRISPR/Cas9 approaches facilitate the introduction of the Venus reporter gene into the human GATA2 locus, as shown by our ability to generate several G2V hESC and hiPSC lines that correctly report HPCs and mast cells. Isogenic G2V hiPSC lines for mast cell disorders can now be readily created by CRISPR/Cas9 engineering of gene mutations (CKIT D816V and/or others) involved in mast cell diseases, such as mastocytosis. The combination of these approaches for staged mast cell differentiation promises to be useful for drug discovery and testing in a disease-specific and patient-specific manner, thus allowing for new treatment strategies and better quality of life for those patients suffering from mast cell-related conditions.

**EXPERIMENTAL PROCEDURES**

**Mouse and Human G2V PSCs**

G2V mESCs were derived from the IB10 ESC line that is a subclone of the E14 ESC line (from the 129/Ola mouse strain) and maintained along with IB10 wild-type control ESC as in Kaimakis et al. (2016) and Kauts et al. (2016, 2018). H1 hESCs (WA01, WiCell) and hiPSCs (Yang et al., 2017) (SFCi55, gift of L. Forrester (Roche)). Human bone morphogenetic protein 4 (10 ng/mL), IL-3 (1 ng/mL), and IL-11 (5 ng/mL) (PeproTech) were added. Medium was replaced daily.

**Mast Cell Generation Culture**

The three-stage culture procedure is summarized in Figure 1A.

**Stage 1. ESC Differentiation (Days 0–10)**

G2V mESCs were trypsinized and feeder depleted by incubation in Iscove’s modified Dulbecco’s medium (IMDM), 20% fetal bovine serum (FBS) (HyClone), and 1% penicillin/streptomycin (P/S) for 30 min at 37°C. For EB formation, G2V mESCs were aggregated by culturing at 25,000 cells/mL in IMDM, 15% FBS, 2 mM GlutaMAX (Gibco), 50 μg/mL ascorbic acid (Sigma), 4 × 10−4 M monothioglycerol (Sigma), and 300 μg/mL transferrin (Roche) in bacterial dishes. After 72 hr the medium was refreshed and supplemented with 5% proteome free hybridoma medium (Gibco). At day 6, medium was supplemented with murine SCF (100 ng/mL), IL-3 (1 ng/mL), and IL-11 (5 ng/mL) (Peprotech) and refreshed every other day. hiPSC differentiation was as described by Kennedy et al. (2012). In brief, hiPSCs were cut using StemPro EZPassage Tool (Thermo Fisher) and aggregates resuspended in StemPro-34 (Invitrogen), 10 ng/mL P/S, 2 mM L-glutamine (Gibco), 1 mM ascorbic acid (Sigma-Aldrich), 4 × 10−4 M monothioglycerol (Sigma-Aldrich), and 150 mg/mL transferrin (Roche). Human bone morphogenetic protein 4 (10 ng/mL), bFGF (5 ng/mL), activin A, 6 mM SB-431542 (selective inhibitor of the TGF-β type I receptor activin receptor-like kinase receptors), vascular endothelial growth factor (15 ng/mL), Dickkopf-related protein 1 (DKK, 150 ng/mL), IL-6 (10 ng/mL), insulin-like growth factor 1 (25 ng/mL), IL-11 (5 ng/mL), SCF (50 ng/mL), erythropoietin (EPO, 2 U/mL), thrombopoietin (TPO, 30 ng/mL), IL-3 (30 ng/mL), and Fms-related tyrosine kinase 3 ligand (FLT-3L, 10 ng/mL) (Peprotech) were added.

**Stage 2. OP9 Co-culture for Hematopoietic/Mast Cell Commitment (Days 10–14)**

At day 10, EBs were washed in PBS, incubated with TrypLE Express (Gibco) (37°C, 3–5 min), and deactivated with PBS, 10% calf serum, an 1% P/S. Cells were suspended with a P1000 pipette. Ten thousand V+ cells were sorted and plated on 30,000 OP9 cells pre-seeded 1 day earlier in 24-well plates in a minimal essential medium, 10% heat-inactivated FBS, 1% P/S, 20 ng/mL FLT-3L, 20 ng/mL IL-7 and/or 20 ng/mL IL-6, and 50 ng/mL SCF (Peprotech). For hiPSC culture, the same concentration for human cytokines was used (Peprotech). V+ mast cells appeared after 2–4 days and sorted cells used for experiments and further expansion.

**Stage 3. Expansion**

After 4 days of OP9 co-culture, V+ cells were sorted and plated (500 cells/mL) in methylcellulose (STEMCELL Technologies). After 3–4 days, large dense colonies appeared. Colonies were counted after 3–7 days of culture, then cells were harvested by dissolving methylcellulose in PBS and counted by trypan blue exclusion. For replating, colonies were picked and single cells plated into fresh methylcellulose.

**Primary Hematopoietic Cell Cultures**

Adult mice were sacrificed by cervical dislocation. Peritoneal cells were obtained by lavage (PBS, 10% FBS, 1% P/S) as previously described (Meurer et al., 2016) and bone marrow cells by PBS-flushing of the long bones. Cell suspensions were centrifuged for 5 min at 1000 rpm at room temperature, resuspended in RPMI 1640 medium, 2 mM L-glutamine (Gibco), 15% heat-inactivated FBS (Gibco), 1% P/S (Gibco), 0.07% β-mercaptoethanol (Gibco), and 10 mM HEPES (Sigma-Aldrich), and cultured (medium changes every 3 days). For mast cell growth (2–3 weeks), 30 ng/mL IL-3 and 20 ng/mL SCF (Peprotech) were added and for basophil growth (10 days), 10 ng/mL IL-3 was added. All mouse experimentation was performed under the UK Animals Scientific Procedures Act 1986 Project License 70/8076 and performed in compliance with Standards for Care and Use of Laboratory Animals.

**Flow Cytometry**

Venus expression was detected directly. Surface receptor expression was analyzed using antibodies CD45-AF700 (1:400), BioLegend, cat. #103127), CD19-PE (1:200), eBioscience, cat. #12–0193), GR1-APC-Cy7 (1:400; BD Biosciences, cat. # 557661), TER119-BV421 (1:200), CD11b-PerCP-Cy5.5 (1:500), eBioscience, cat. #45-0112-80), FCGrIa-PE (1:800), BioLegend, cat. #134308), CTRT-A567 (1:200), CD34-BV605 (1:400), and CD45-Cy7 (1:200). For intracellular staining, cells were fixed, permeabilized, and stained with antibodies CD45-APCeFluor780 (1:800; eBioscience, cat. #47-1171-80), FCGrIa-PE (1:200), MARK1 (1:200), BioLegend, cat. #108909) for murine cells and CD41-EV (1:50), BioLegend, cat. #303705), FcεRIα-PE (1:50; BioLegend, cat. #334610), and
HEPES buffer (pH 7.4), 50,000 cells/well were activated with phenyl (DNP) IgE (Sigma-Aldrich). Following three washes with supernatant + lysate content). and 2-fold dilutions. with an efficiency range of 95%–105% (all primers in this study).

PMCs were sensitized overnight with 1 Kuehn et al. (2010). In brief, mast cell tryptase release) was determined according to the protocol of instrument logistic (4-PL) curve fit. Mast cell degranulation (was quantified using a Mouse Mast Cell Tryptase (MCT) ELISA After centrifugation, tryptase concentration in the supernatant was determined using a colorimetric assay with absorbance measured at 405 nm (Varioskan Flash 10.7). The reaction was stopped with glycine buffer (400 mM, pH 3.5 mg/mL p-nitrophenyl-N-acetyl-β-D-hexosaminidase released = 100 * (supernatant content)/(supernatant + lysate content)). Some human sample slides were stained with a Rapid Romanowsky Stain Pack kit (TCS Biosciences). An Axioskop2 (Zeiss) microscope with 40× objective was used.

Mast Cell Activation/Degranulation Analyses

Mast cells (stage 3) (1 × 10⁶) were resuspended in 1 mL of PBS and stimulated with c48/80 (Sigma) (5 μg/mL, 60 min, 5% CO₂, 37°C). After centrifugation, tryptase concentration in the supernatant was quantified using a Mouse Mast Cell Tryptase (MCT) ELISA Kit (Cusabio). A standard curve was generated using a four-parameter logistic (4-PL) curve fit. Mast cell degranulation (β-hexosaminidase release) was determined according to the protocol of Kuehn et al. (2010). In brief, 2G2-v-mESCS-MCs and control PMCs were sensitized overnight with 1 μg/mL mouse anti-dinitrophenyl (DNP) IgE (Sigma-Aldrich). Following three washes with HEPES buffer (pH 7.4), 50,000 cells/well were activated with DNP-HSA (Sigma-Aldrich) and incubated in 37°C for 60 min. Supernatants were collected and cells lysed using 0.1% Triton X-100 in HEPES buffer. β-Hexosaminidase activity in supernatants and cell lysates was measured using a colorimetric assay with 3.5 mg/mL p-nitrophenyl-N-acetyl-β-D-glucosamidase (PNAG; Sigma-Aldrich) as a substrate. After 90 min incubation at 37°C, the reaction was stopped with glycine buffer (400 mM, pH 10.7). The absorbance was measured at 405 nm (Varioskan Flash microplate reader, Thermo Scientific). The percentage of β-hexosaminidase release was calculated according to the formula: % β-hexosaminidase released = 100 × (supernatant content)/(supernatant + lysate content).

Expression Analysis

Total RNA was extracted using an RNA mini or micro kit (Qiagen) and standardized to 100 ng/mL. cDNA was synthesized using Superscript Vilo synthesis kit (Invitrogen) at 25°C for 10 min, 42°C for 60 min (primer extension), and 85°C for 5 min (inactivation) in a Thermo Cycler (MJ Research PTC 200 BC-MJPC200). A cDNA standard curve for qPCR primer efficiency validation was made using an RNA dilution series (murine; HMC-1). Together with standard curve R² value, efficiency (E, %) of all the primer sets was calculated by formula E = (10(-1/Slope) - 1) × 100 in 10^- and 2-fold dilutions. ∆∆Ct analysis was performed for primer sets with an efficiency range of 95%–105% (all primers in this study). TaqMan PCR was used for real-time RNA quantification. Primer sets were designed using the “Universal ProbeLibrary Assay Design Center.” Semi-quantitative RT-PCR was performed using BioMixRed (Bioline). For human Venus-sorted samples, total RNA was isolated and reverse transcribed using oligo-dT (Life Technologies) and SuperScript III (Life Technologies). qRT-PCR used Fast SYBR Green Master Mix (Life Technologies). Primers are listed in Table S1.

Statistics

For two-group analysis, an unpaired two-tailed t test was used. One-way ANOVA was used for multiple-group comparison, followed by Kruskal-Wallis as a secondary test and Dunn’s multiple comparisons test. Results are statistically significant at p < 0.05. Data are shown as mean ± SEM, n = number of independent experiments. Data analysis was done using GraphPad Prism (GraphPad Software).

SUPPLEMENTAL INFORMATION

Supplemental Information includes Supplemental Experimental Procedures, three figures, and one table and can be found with this article online at https://doi.org/10.1016/j.stemcr.2018.08.007.

AUTHOR CONTRIBUTIONS


ACKNOWLEDGMENTS

We thank all the lab members for helpful discussions and support with the experiments, and the QMRI Flow facility for FACS sorting. The authors acknowledge the grant support of the Landsteiner Society for Blood Research (LSBR 1109), ZonMW-Netherlands Scientific Research Council TOP (91211068), the European Research Council advanced grant (341096), and NIHR grant (RP-PG-0310-1002). B.G. and A.C.W. were supported by Bloodwise, NIHR, and core support funding from the Wellcome Trust to the Cambridge Stem Cell Institute.

Received: January 23, 2018
Revised: August 7, 2018
Accepted: August 8, 2018
Published: September 6, 2018

REFERENCES


